National ANTIBIOTIC RESISTANCE Portal
Private Collaborative Access

French National ANTIBIOTIC RESISTANCE Portal

Antibiotic therapy, everyone’s business

The rise in antimicrobial resistance is an increasingly critical public health issue worldwide. It requires the mobilisation of various public and private players in the healthcare sector. Among them, pharmaceutical companies such as Pfizer have been involved for years in the fight against antimicrobial resistance and are calling for the necessary changes at various levels.
Read more

Social science perspectives on understanding and overcoming antibiotic dependence

It is now common knowledge that antimicrobial resistance (AMR) is a social problem that must not only be studied as a biomedical challenge, but for which other factors – i.e. sociological, economic, political and cultural determinants – must be taken into account. Most research into social factors has been conducted from a social psychological and behaviourist perspective, but it tends to overlook the structural and organisational determinants that provide the framework for individual behaviour.
Read more

Europe united in the fight against antibiotic resistance.

Antibiotic resistance (AMR) is now one of the major public health challenges worldwide. Antibiotics, which are essential to modern medicine, are used to treat and prevent many infections, particularly during surgery, transplants and chemotherapy.
Read more

Attempting to improve access to “forgotten” antibiotics in Europe

Reliable access to antibiotics is an essential part of a functioning modern healthcare system, meaning that infections can be treated and advanced procedures like chemotherapy and organ transplants can be performed at acceptable risk levels.
Read more

Diagnostic tests – an asset for the proper use of antibiotics

Since the COVID-19 pandemic, diagnostic tests such as PCR and rapid tests have become part of the public lexicon. Rapid diagnosis also plays a crucial role in identifying and treating microbial infections, and in slowing down antimicrobial resistance (AMR).
Read more

Transferable exclusivity extensions to fund research into antibiotic resistance

While the need for new antibiotics is urgent and should naturally attract investors, there is too little innovation and R&D in the field of antibiotic resistance. We are facing what is known as a market failure, the main reason for which is linked to the need to preserve their value for public health. Indeed, the consumption of antibiotics has a private, short-term value for each patient, but it also has an impact on the population as it promotes the development of antibiotic resistance.
Read more

Antimicrobial Resistance: The Silent Pandemic

Antimicrobial resistance (AMR), a ‘silent’ or ‘overlooked’ pandemic, 1,2 is classed as a threat to global health and development by the World Health Organization (WHO). If left unchecked, it could cause 10 million deaths per year by 2050,3 cost the global economy US$100tn,1 and drive 28 million people into extreme poverty.4 This cannot be overlooked, and we cannot be silent — the development of novel antimicrobials must be a public health priority.
Read more

Why a french national ANTIBIOTIC RESISTANCE portal?

The French National Antibiotic Resistance portal, which results from the PPR on Antibiotic Resistance, is intended for the scientific community as a common, intersectoral and interactive gateway. It identifies public and private actors, platforms and networks, coordination activities, events and research projects in the field on antibiotic resistance.

Projects and actions supported

The PPR on Antimicrobial Resistance funds for €40M, 11 research projects, a meta-network of professionals, a multi-omics data platform, a digital observatory of social dimensions and research positions.
See all funded projects

Priority Research Programme on
ANTIBIOTIC RESISTANCE

First call for projects of the Antibiotic resistance programme

Governance and coordination

Microbiology and multi-omics data platform

Meta-network of professionals

Observatory dedicated to social sciences

Research network with low- and middle-income countries

“One Health”


The “One Health” approach conceptualises
human, animal and environmental health as
one, integrated system. As dissemination of
resistant bacteria between humans, animals and
the environment is a key factor in the spread of
antibiotic resistance, it is essential to develop
control strategies that do not dissociate humans
from their environment. This underlines
the urgent need to support a holistic
research response to challenges in
these three sectors.

News

See all the news

Our videos

Priority Research Program (PPR) Antibiotic Resistance

Could we die tomorrow from a common infection due to a lack of effective treatment? Antibiotic resistance has become a huge public health problem, with interdependence between humans, animals, and the environment.

Antibiotic resistance: tools and structuring networks

The Priority Research Program (PPR) on Antibiotic Resistance covers the optimization of use, therapeutic innovation, and monitoring of emergence, among other topics. But that is not enough.

Read more

Controlling the emergence of antibiotic resistance

To limit the development of antibiotic resistance, we can optimize usage, innovate with new treatments, and also draw on the humanities and social sciences.